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Abstract
Objective: To study usefulness of bone marrow progenitor cells (BPCs) epigenetically altered by chromatin modifying
agents in mediating heart repair after myocardial infarction in mice.
Methods and Results: We tested the therapeutic efficacy of bone marrow progenitor cells treated with the clinically-used
chromatin modifying agents Trichostatin A (TSA, histone deacetylase inhibitor) and 5Aza-2-deoxycytidine (Aza, DNA
methylation inhibitor) in a mouse model of acute myocardial infarction (AMI). Treatment of BPCs with Aza and TSA induced
expression of pluripotent genes Oct4, Nanog, Sox2, and thereafter culturing these cells in defined cardiac myocyte-
conditioned medium resulted in their differentiation into cardiomyocyte progenitors and subsequently into cardiac
myocytes. Their transition was deduced by expression of repertoire of markers: Nkx2.5, GATA4, cardiotroponin T,
cardiotroponin I, a-sarcomeric actinin, Mef2c and MHC-a. We observed that the modified BPCs had greater AceH3K9
expression and reduced histone deacetylase1 (HDAC1) and lysine-specific demethylase1 (LSD1) expression compared to
untreated BPCs, characteristic of epigenetic changes. Intra-myocardial injection of modified BPCs after AMI in mice
significantly improved left ventricular function. These changes were ascribed to differentiation of the injected cells into
cardiomyocytes and endothelial cells.
Conclusion: Treatment of BPCs with Aza and TSA converts BPCs into multipotent cells, which can then be differentiated into
myocyte progenitors. Transplantation of these modified progenitor cells into infarcted mouse hearts improved left
ventricular function secondary to differentiation of cells in the niche into myocytes and endothelial cells.
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Introduction
Bone marrow-derived progenitor cells (BPCs) and endothelial
progenitor cells (EPCs) from the bone marrow can mediate
neovascularization in the ischemic myocardium and improve pump
function of the heart [1,2]. However, stem cell therapy involving
BPCs and EPCs has often produced small and variable effects and,
importantly, it remains unclear whether these cells are capable of
inducing myogenesis and myocardial regeneration [3,4]. The
protective effects also appear to be due to release of humoral
factors [5]. Because of the variability of the responses using BPCs
and EPCs [3–5], we addressed the question whether BPCs can be
improved by modifying them pharmacologically such that there is
improved engraftment and myocardial regeneration. Here we used
the strategy of treating BPCs with available chromatin modifying
agents prior to their transplantation. We used trichostatin A (TSA, a
histone deacetylase inhibitor) and 5Aza-2-deoxycytidine (Aza, a
DNA methylation inhibitor) [6] based on the precept that DNA
demethylation and histone acetylation are key steps required for
epigeneticmodificationofcells[7,8].Theseagentshavebeen shown
to alter cell fate [9,10] and differentiate mesenchymal stem cells
(MSCs) into cardiac myocytes (CMCs) [11]. We observed that these
drugs used together inducedconversion of BPCs to multipotent cells
(referred to as eiBPCs). The cardiac progenitor cells generated from
eiBPCs were used for transplantation into mouse infarcted hearts.
We investigated how these agents converted BPCs into multipotent
eiBPCs and effects of transplantation of cardiac progenitors derived
from eiBPCs on cardiac function. We observed that combined Aza
and TSA treatment of BPCs induced epigenetic changes charac-
terized by greater AceH3K9 expression and reduced histone
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e22550deacetylase1 (HDAC1) and lysine-specific demethylase 1 (LSD1)
expression compared to untreated BPCs. These epigenetic changes
induced expression of Oct4, Nanog and Sox2, transcription factors
in BPCs. Transplantation of cardiac progenitors derived from
eiBPCs into infarcted mouse hearts significantly improved left
ventricular function that was coupled to differentiation of the
injected cells into CMCs and endothelial cells at sites of
transplantation.
Materials and Methods
Cell culture
Mouse bone marrow derived progenitor cell (BPC) culture was
carried out as described [12]. Mononuclear cells isolated from the
tibias and femurs of GFP-expressing transgenic C57BL/6-TgN
(ACTbEGFP) mice were cultured in EBM-2 medium supple-
mented with (SingleQuot Kit; Clonetics) 5% FBS on cell-culture
dishes coated with 0.1% rat vitronectin/gelatin. After 4 days in
culture, the adherent cells were reseeded (5610
4 cells/cm
2)o n
0.1% vitronectin/gelatin-coated 10 cm culture dishes and 4-well
chamber slides and cultured for 3 additional days. Cells in 4-well
slides were co-incubated with DiI-acLDL (Biomedical Technolo-
gies) for 1 hour, stained with fluorescein isothiocyanate–conjugat-
ed Banderia simplicifolia lectin 1 (FITC-BS1), and viewed under
fluorescence microscope. Majority of these cells were double-
stained with these markers defining them as endothelial-lineage
cells [12]. These cells were further characterized by flow cytometry
using stem and progenitor cell marker antibodies. Day-7 BPCs
growing in 10 cm culture dishes were used for the chemical
modification experiments using Aza and TSA described below.
Quantitative reverse transcriptase-polymerase chain
reaction (qRT-PCR)
Day-7 BPCs were treated with Aza (0, 10, 25, 50 and 100 nM)
or TSA (0, 5, 10, 25 and 50 nM) or both drugs combined for 4
days. Total cellular RNA was obtained for qRT-PCR analysis to
determine mRNA expression of pluripotency markers [13,14].
The gene expression profiles of Primer and probe sequences
specific for specific target genes are given in Table 1. Relative
mRNA expression of target genes was normalized to endogenous
18S control gene (Applied Biosystems). Results were expressed as
fold change in expression and values were calculated as ratio of
induced expression-to-control expression.
Polymerase chain reaction (PCR)
Genomic DNA was obtained from tissue sections from un-
injected (control) and BPC- and eiBPCs-derived cardiac progen-
itor-injected mouse hearts. Sections were stained with anti-EGFP
antibody to identify areas of injected cells present in the
myocardium and these sections were used for PCR analysis.
Additionally, random samples of recipient spleen, lung, liver and
kidney were also used for DNA extraction to compare with
responses occurring in the heart. PCR was conducted for EGFP to
identify DNA of EGFP-labeled transplanted cells. DNA was
extracted with QIAamp DNA micro kit (Qiagen); 100 ng DNA
was mixed with primers for EGFP (Table 1). Final PCR products
were run on agarose gel for detection of bands corresponding to
EGFP.
Differentiation of eiBPCs into cardiomyocytes
To determine differentiation potential of re-programmed BPCs,
termed eiBPCs, into CMCs, the eiBPCs were cultured for 5 days in
complete DMEM containing CMC induction medium with 5 ng/
mL LIF and 3 ng/mL bone morphogenetic protein-2 (BMP-2) in
6-well culture plates (10
6 cells per well) as well as 4-well chamber
slides (10
4 -cells per well) coated with 0.1% gelatin as in [13,14].
Total cellular RNA was obtained from 6-well culture plates and
qRT-PCR analysis of mRNA expression of CMC markers was
carried out (Table 1); the markers used were GATA4, Nkx2.5,
cardiotroponin T (CTT), CTI, a-sarcomeric actinin (a-SA), Mef2c,
and MHC-a. For protein expression, cells were cultured for 10 days
and protein expression was determined by immunochemical
staining. For transplantation into myocardial infarction model,
eiBPCs werecultured in CMC-conditioned mediumfor 24 hoursto
commit the cells towards CMC lineage [13] before transplantation.
Immunofluorescence staining
Protein expression was evaluated by immunofluorescence
staining as in [13,14]. Briefly, cultured cells or cardiac tissue was
rinsed once with phosphate-buffered saline (PBS) and fixed with
4% paraformaldehyde (Sigma) in PBS for 30 min, then rinsed
three times with PBS, permeabilized with 0.3% Triton X-100
(Sigma) in PBS for 5 min, washed twice with PBS, and incubated
overnight at 4uC with primary antibodies (against Oct4, Nkx2.5,
Gata 4, MAP-2, MBP, GFAP, CTT, a-SA, GFP and Ki67) diluted
with 1% FBS in PBS. After 3 washes with PBS, cells were
incubated with specific secondary antibodies for 1 hour at 37uC,
Table 1. Primers and Sequences.
Primers used for qRT-PCR
Gene name Sequences
CTT F: GACAGACTGGTCGGGAGATGA
R: CCCCCATGTAGTCGATGTTCA
C-Kit F: TGGCTCTGGACCTG R: ACAATTCTTGGAGGCGAGGAA
eNos F: TCTGCGGCGATGTCACTATG
R: CATGCCGCCCTCTGTTG
Gata4 F: GCGCCCCATCAAGACAGA R:
GTGGCCGGACACAGTACTGA
Nanog F: GCTCAGCACCAGTGGAGTATCC
R: TCCAGATGCGTTCACCAGATAG
Nkx2.5 F: CTTCAAGCAACAGCGGTACCT
R: CGCTGTCGCTTGCACT
Oct4 F: TCGGACCAGGCTCAGAGGTA
R: ATCCCTCCGCAGAACTCGTA
Sox2 F: AAACCAAGACGCTCATGAAGAAG
R: CGCTCGCCATGCTGTTC
VE-Cadherin F: GTGGATGAGCCCCCTGTCT R: CAGCGGTTTCTTC
Flk-1 F: GAGCTCTCCGTGGATCTGAAA R: AACAAAGCCTGAG
IL-10 F: CAGCCGGGAAGACAATAACTG
R: CCGCAGCTCTAGGAGCATGT
IL-10R F: TGTCTGTATGCAAAGCTTGGAAAT
R: GTCTGTGCCCGCTTTCTCA
TNF-a F: GGCTGCCCCGACTACGT
R: AGGTTGACTTTCTCCTGGTATGAGA
MCP1 F: CTTCCTCCACCACCATGCA R: CCAGCCGGC
IL-6 F: TTCCATCCAGTTGCCTTCTTG
R: GGGAGTGGTATCCTCTGTGAAGTC
IL-1b F: CTACAGGCTCCGAGATGAACAAC
R: TCCATTGAGGTGGAGAGCTTTC
Primers used for PCR
eGFP (315 bp): F: 59- ATG GTG AGC AAG GGC GAG GAG CTG -39
R: 59- GCC GTC GTC CTT GAA GAA GAT GGT G -39
doi:10.1371/journal.pone.0022550.t001
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visualize cell nuclei, rinsed 3 times with PBS, dried, and mounted
in Vectashield mounting medium for fluorescent imaging. All
immunofluorescence staining was photographed using either
confocal and immunofluorescence microscope.
Western blot analysis of AceH3K9, HDAC1 and LSD1
proteins
Immunoprecipitation and Western blot analyses of AceH3K9,
HDAC1 and LSD1 proteins were performed in BPCs and eiBPCs
as in [13] using antibodies purchased from Cell Signaling
Technology, USA.
Chromatin immunoprecipitation assay (ChIp)
ChIp assaywasperformed for the Oct4promoterinBPCs, eiBPCs
and mouse ESCs as described [14,15] to identify transcription factors
binding to Oct4 following treatment with Aza and TSA.
Cell viability and proliferation assays
Viability and proliferation of the modified BPCs was
evaluated by Trypan-blue exclusion and MTT assays, respec-
tively. BPCs were cultured with different concentrations of Aza
and TSA in 12-well culture plates for 24 or 48 hours, cells were
harvested, exposed to Trypan blue solution (final concentration
0.1%), and number of viable (unstained) and non-viable (stained)
cells were counted with a hemocytometer. Effects of Aza and
TSA on BPC proliferation was determined by 3, 4, 5-
(dimethylthiazol-2-yl) 2, 5- diphenyl tetrazolium bromide
(MTT) assay according to manufacturer’s instruction (Cell
Proliferation Assay kit Promega). Briefly, 10
5 cells were cultured
in 96-well culture plate (200 ul/well) in DMEM containing 10%
FBS in the presence of 0, 25, 50 and 100 ng/ml 5Aza or 0, 10,
25, 50 nm/ml TSA or combination of both for 48 hours at
37uC. MTT assay results were confirmed by manual cell
counting under microscope.
Figure 1. Characterization of Day-7 BPCs and their conversion into multipotent progenitor cells using Aza and TSA.
Immunofluoresent analysis of BPCs stained with DiI-acLDL (red), Isolectin B4 (green), nuclei (blue,) and co-localized cells (yellow) (A); FACS analysis
of BPCs for specific progenitor markers, (B); Dose-response relationship of Aza- or TSA-treated BPCs. RT-PCR analysis of Oct4 and Nanog transcripts
after treatment of BPCs with Aza (0, 10, 25, 50, 100 nM) or TSA (0, 5, 10, 25, 50 nM) for 48 hours, (C); RT-PCR analysis of Oct4, Nanog and Sox2
transcripts after treatment of BPCs with combination of Aza (0, 10, 25, 50 nM) and TSA (0, 5, 10, 25 nM) for 48 hours, (D); Day-10 Oct4 protein
expression by immunofluoresence, (E); Day-10 Oct4 protein expression by Western blotting, (F); RT-PCR analysis of endothelial markers eNOS and VE-
cadherin transcripts after treatment of BPCs with Aza (50 nM) or TSA (25 nM) or combination of both drugs for 48 hours, (G); RT-PCR analysis; each
bar represents mean 6 S.E of 3 replicate experiments. Fold expression was calculated as ratio of experimental cell expression-to-expression in control
cells. *p,0.01 vs. control,
{p,0.001 vs. control.
doi:10.1371/journal.pone.0022550.g001
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All procedures were performed in accordance with guidelines of
Institutional Animal Care and Use Committee of University of
Illinois at Chicago (ACC No: 09-061 approved dated 05/08/
2009). The study involved 8-week-old male C57BL/6J mice
(n=30); Jackson Laboratories). Mice underwent surgery to induce
AMI by ligation of left anterior descending coronary artery
[16,17]. Animals subdivided into 3 groups received intramyocar-
dial injection of 5610
5 GFP+cardiac progenitors derived from
eiBPCs (treated for 24 hours with cardiomyocyte specific medi-
um), control BPCs, or saline, respectively, in a total volume of
10 uL at 5 sites (basal anterior, mid-anterior, mid-lateral, apical
anterior and apical lateral) in the peri-infarct area immediately
after surgery.
Left ventricular function and histology
Mice underwent echocardiography just before MI (base level)
and at 1, 2, and 4 weeks after AMI as described [16,17]. Trans-
thoracic echocardiography was performed with a 6- to 15-MHz
transducer (SONOS 5500, Hewlett Packard). Two-dimensional
images were obtained in the parasternal long and short axis and
apical 4-chamber views. M-mode images of the left ventricular
short axis were taken just below the level of mid-papillary muscles.
Left ventricular end-diastolic and end-systolic dimensions were
measured and functional shortening was determined according to
modified recommendations of American Society of Echocardiog-
raphy. A mean value of 3 measurements was determined for each
time point. On day 28 post-AMI, mice were euthanized and aortas
were perfused with saline, hearts were removed and sliced into 4
transverse sections from apex to base and fixed with 4%
paraformaldehyde, methanol, or frozen in OCT compound and
sectioned into 5-mm thickness slices. Immunofluorescence staining
was performed to determine myocyte and endothelial cell
differentiation of transplanted cells. For assessment of fibrosis,
tissues sections were frozen in OCT compound and sectioned for
elastic tissue/trichrome to measure average ratio of the external
circumference of fibrosis area to left ventricular area.
Apoptosis assay
To assess survival of transplanted cells as well as effects of cell
transplantation on survival of resident myocytes, apoptosis assay
was performed on heart tissue collected at different time points.
Cell death was assessed using the TUNEL kit according to
manufacturer’s instruction (Roche Applied Science). After TU-
NEL assay staining, sections were examined by confocal
fluorescence microscopy.
Figure 2. Viability and proliferative potential of Aza- and TSA-treated BPCs. Trypan blue dye exclusion viability assay in BPCs treated with
5Aza and TSA (A). Proliferation of treated BPCs assessed by MTT method (B). Cell proliferation assessed by hemocytometer cell counting after
48 hours (C). Each bar represents mean 6 S.E of 3 replicated experiments. *p,0.05 vs. control.
doi:10.1371/journal.pone.0022550.g002
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transplanted cells
We measured mRNA levels of TNF-a, IL-1b, IL-6, MCP-1 and
IL-10 in heart tissue bordering the infarcted myocardium as
described [18].
Staining for endothelial marker CD31
De-paraffinized heart tissue section slides were incubated for
30 min in peroxidase suppressor to quench endogenous perox-
idase activity. After washing slides two times for 3 min with a
wash buffer, blocking buffer was added and then incubated for
30 min. The tissue was incubated for 30 min with anti-CD31
antibody and slides were washed two times for 3 min with wash
buffer. Again the tissues were incubated for 30 min with HRP-
conjugated secondary antibody and slides were washed 3 times
for 3 min each with wash buffer. Finally, the metal enhanced
DAB Substrate was added and incubated until the desired
staining was achieved.
Statistical analysis
All experiments were made at least 3 times. Results are
presented as mean+SEM. Comparisons were performed by
ANOVA (GB-STAT; Dynamic Microsystems) or x
2 test for
percentages. All tests were 2-sided, and probability value of ,0.05
was considered as statistically significant.
Results
Expression of pluripotent genes in BPCs after treatment
with Aza and TSA
On day 7, BPCs obtained from C57BL/6J mouse bone marrow
as described [12] were analyzed by immunofluorescence and
flowcytometry (Figure 1A, B). Most cells were positive for Dil-
acLDL and showed binding to fluorescein isothicyanate-conjugat-
ed Banderia simplicifolia lectin 1 (FITC-BS1). FACS analysis also
showed BPCs were a heterogeneous population. They were
positive for progenitor cell markers such as CD34 (17%), CD133
(10%), Sca1 (100%), and c-kit (12%) and some were also positive
Figure 3. Modification of Aza- and TSA-treated BPCs reflected in expression of AceH3K9 and LSD1 and acetylation of Oct4.
Treatment of BPCs with Aza + TSA (eiBPCs) shows increased AceH3K9 expression (A), decreased HDAC1 expression (B), and decreased LSD1
expression (C) assessed Western blotting. Promoter of Oct4 was analysed by ChIp using anti-AceH3K9 antibody or anti-IgG control antibody.
Acetylation status of histone H3 showed that Oct4 promoter was highly acetylated in mouse ESCs (positive control), was not acetylated in untreated
BPCs, but was significantly acetylated in Aza- and TSA-treated BPCs (eiBPCs) (D). Results show representative data of n=3. *P,0.05 vs. control,
**p,0.01 vs. control,
{p,0.005 vs. control.
doi:10.1371/journal.pone.0022550.g003
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BPCs were treated for 4 days with Aza alone, TSA alone, or both
Aza and TSA at various concentrations. BPCs treated with Aza or
TSA alone (Figure 1C) or with both agents in combination
induced expression of Oct4, Nanog and Sox2 (Figure 1D,
p,0.001 control vs. Aza+TSA treatment group). Maximum
expression of these factors occurred at combined concentrations
of 50 nM Aza and 25 nM TSA. Immunofluorescence analysis of
Oct4 expression showed that BPCs treated with Aza+TSA showed
significantly up-regulated expression of pluripotent genes at
passage 0 (Figure 1E) but expression decreased markedly by
passage 6 (data not shown). The expression of Oct4 gene transcript
was supported by Oct4 Western blot protein expression data
(Figure 1F). The results shown in Figure 1A-E demonstrate that
pluripotent genes in BPCs were activated by co-treatment with
Aza and TSA in a concentration-dependent manner. We also
observed by qRT-PCR that BPCs treated with 50 nM Aza and
25 nM TSA resulted in silencing of eNOS and VE-cadherin genes
compared to control cells (Figure 1G), suggesting that these drugs
promoted de-differentiation of endothelial cells present in the BPC
population.
Aza and TSA do not affect BPC viability
BPCs were cultured with different concentrations of Aza and
TSA in 12-well culture plates for 24 or 48 hours, cells were
harvested, exposed to Trypan blue solution (final concentration
0.1%), and number of viable (unstained) and non-viable (stained)
cells were counted with a hemocytometer. Treatment with up to
50 nM Aza and 25 nM TSA had no effect on cell viability
(Figure 2A, p=0.09). The modified BPCs also showed normal
ability to proliferate (Figure 2B, C p,0.05)
Epigenetic changes in Aza- and TSA-treated BPCs
We determined whether Aza and TSA treatment of BPCs
altered acetylation and methylation status of AceH3K9, HDAC1,
and LSD1 proteins involved in induction of multipotency [19].
BPCs were treated with 5Aza and TSA, either alone or in
combination for 2 days. As shown in Figure 3A, expression of
acetylated H3 lysine9 (AceH3K9) protein was significantly
increased in BPCs treated with TSA alone (p,0.01) or with Aza
plus TSA (p,0.005) compared to controls. HDAC1 protein
expression decreased after treatment of BPCs with either TSA
alone (p,0.005) or combination of Aza+TSA (p,0.005) com-
Figure 4. Conversion of eiBPCs into myocytes. eiBPCs were cultured in conditions favoring their transition into cardiac progenitors (see
Method), and RT-PCR analysis was carried out. Results show Flk1 and c-kit transcripts after 24 hours in cardiomyocyte differentiation medium (A).
Protein expression of Flk1 (green) and c-kit (red) after 24 hours in cardiomyocyte differentiation medium analyzed by immunofluorescence showing
higher number of Flk1+/c-kit+ cells (yellow). Greater number of cardiac progenitor cells was evident in BPCs treated with combination of Aza and TSA
vs. treatment with each agent alone or in control cells (B). Differentiated cardiac progenitor cells derived eiBPCs at 5 days after culture in myocyte
differentiation medium expressed the cardiomyocyte specific gene transcripts Gata4, Nkx2.5, CTT and a-SA (C) and Mef2c, MHC-a and CTI as
determined by qRT-PCR (D). Response was evident only in BPCs treated with Aza (50 nM) + TSA (25 nM) for 5 days. Each bar represents mean 6 S.E of
3 replicated experiments. Image magnification 400X. *p,0.01 vs. control, #p,0.005 vs. control,
{p,0.001 vs. control.
doi:10.1371/journal.pone.0022550.g004
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treated BPCs displayed decreased LSD1 expression (p,0.05)
(Figure 3C).
We also determined whether Aza and TSA induced changes in
AceH3K9 protein interaction with Oct4 promoter [14] to assess
whether these agents can epigenetically modify BPCs. As shown in
Figure 3D, Oct4 promoter was highly acetylated in positive
control mouse ESCs, whereas acetylation of H3 region in Oct4
promoter was not detected in untreated BPCs but it was much
evident in the treated BPC (p,0.05).
Differentiation of Aza- and TSA-modified BPCs into
cardiomyocytes
To address whether Aza and TSA modified BPCs (eiBPCs)
could give rise into myocyte progenitor lineage cells and
cardiomyocytes, eiBPC were cultured for 5 or 10 days in CMC
induction medium. We observed that cardiac progenitor cell
markers Flk1 and c-kit were up-regulated as early as 24 hr after
combined treatment with Aza and TSA compared to control or
BPC treated with Aza or TSA alone (Figure 4A, B). Cardiomy-
ocyte specific markers, GATA4, Nkx2.5, CTT, a-sarcomeric
actinin, Mef2c, MHC-a and CTI were up-regulated after
combined treatment of Aza and TSA at day 5 compared to BPCs
treated with Aza or TSA alone (Figure 4C, D; P,0.001 control vs.
cells treated with both Aza and TSA). eiBPCs or cardiac
progenitor cells derived from eiBPCs failed to differentiate into
endodermal lineage of cells and did not form teratomas in SCID
mice (data not shown) suggesting that eiBPCs or cardiac
progenitors derived from eiBPCs had been partially re-pro-
grammed but were not pluripotent.
Intracardiac injection of eiBPC-derived cardiac
progenitors improves post-infarction left ventricular
function
We used a standardized mouse AMI model [16,17] to test the
efficacy of cardiac progenitors derived from eiBPCs (as described
Methods) in improving LV function. Physiological assessment of
LV function was made before AMI and on days 7, 14 and 28 post-
AMI. The day 28 post-AMI echocardiography showed signifi-
cantly improved LV diastolic dimensions (LVDd) and percentage
of LV fractional shortening (%LVFS) in mice transplanted with
eiBPCs and BPCs compared to saline control (Figure 5A, B).
Mouse hearts treated cardiac progenitors derived from eiBPCs
had better functional outcome post-AMI than BPC treatment
Figure 5. Intracardiac injection of eiBPC-derived cardiac progenitors improves left ventricular (LV) function and decreases
myocardial fibrosis in mouse AMI model. Echocardiographic LV function parameters measured 1, 2 and 4 weeks after AMI and cell
transplantation showed greater recovery in LV diastolic dimension (LVDd) and LV fractional shortening (LVFS) after transplantation of cardiac
progenitors derived from eiBPCs vs. BPC transplantation and saline injected controls, (A, B); Trichrome staining of cardiac tissue show markedly
enlarged LV in saline and was less enlarged after BPC transplantation and transplantation of cardiac progenitors derived from eiBPCs (C);
Quantification of relative fibrotic areas in hearts in each group (D). Quantification of capillary density measured by CD31 DAB staining showing
greater staining after transplantation of BPCs and cardiac progenitors derived from eiBPCs relative to saline control group (E). Each bar represents
mean 6 S.E of 3 replicated experiments. *p,0.05 vs. saline, **p,0.05 vs. BPCs,
{p,0.001 vs. saline.
doi:10.1371/journal.pone.0022550.g005
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myocardium in hearts treated with Aza- plus TSA-modified BPCs.
Masson’s trichrome-stained sections showed markedly enlarged
LV in saline-injected AMI mice and LVs were less enlarged in
mouse hearts injected with Aza- plus TSA-modified BPCs
(Figure 5C). Heart sections were also quantified for % LV fibrosis
as the ratio of length of fibrosis scar-to-LV circumference. We
observed marked reduction in LV fibrosis in hearts treated with
eiBPC-derived cardiac progenitors compared with hearts treated
with BPCs or saline (Figure 5D). We also examined the capillary
density in ischemic area by DAB staining using anti-CD31
antibody marking for capillaries (Figure 5E). Five randomly
chosen sections were quantified in microscopic visual fields on
each slide and mean was calculated. We observed a closely similar
number of capillaries in BPC-transplanted hearts (2863) and
eiBPC-derived cardiac progenitor-transplanted hearts (2562)
(Figure 5E, P=0.06), suggesting that propensity of BPCs to
differentiate into endothelial cells was similar to cardiac progen-
itors from eiBPCs.
Myocardiac injection of eiBPC-derived cardiac progenitor
cells suppresses inflammation
To determine effects of cardiac progenitors derived from
eiBPCs on expression of pro-inflammatory and anti-inflammatory
cytokines and chemokines (TNF-a, IL-1b, IL-6, MCP-1 and IL-
10) in the myocardium at 3 days post-AMI was assessed by qRT-
PCR. Expression of pro-inflammatory cytokines and chemokines
was increased in myocardium of saline-treated and was decreased
in BPC-treated (Figure 6A-D, p,0.01 vs. saline) and eiBPC-
derived cardiac progenitor-treated myocardium (Figure 6A-D,
p,0.005 vs. saline, P,0.05 vs. BPC). The anti-inflammatory
cytokine IL-10 mRNA expression was increased in eiBPC-derived
cardiac progenitor group compared to saline- or BPC-treated
group (Figure 6E, p,0.01 vs. saline, p,0.05 vs. BPC) treated
myocardium. Even in non-injected eiBPC-derived cardiac pro-
genitors, there was increased IL-10 and IL-10R mRNA expression
vs. BPCs (Figure 6F).
Myocardial injection of cardiac progenitors derived from
eiBPCs induces expression of cardiac cells and new vessel
formation
Immunofluorescence staining was performed to determine in situ
differentiation of transplanted GFP+eiBPC-derived cardiac pro-
genitors in the myocardium. The 28 days post-cell injected heart
tissue sections were co-stained with CMC tissue markers
cardiotroponin T (CTT) (Figure 7A) and a-SA (Figure 7B). The
GPF+ cells (green) expressing the two CMC proteins (red) were
double positive (yellow) merged images indicating the co-
Figure 6. Transplantation of eiBPC-derived cardiac progenitors suppresses inflammation. mRNA expression of (A) IL-b;( B) TNF-a;( C) IL-6;
(D) MCP1; (E) IL-10 at the infarct border zone. *p,0.01 vs. saline, #p,0.05 vs. BPCs,
{p,0.005 vs. saline. Cardiac progenitors derived from eiBPCs
significantly expressed IL-10 and IL-10R transcripts. Cardiac progenitors were obtained by culturing eiBPCs for 24 hours in cardiomyocyte conditioned
medium (as described in Methods) and cells were obtained for qRT-PCR analysis. IL-10 and IL-10R mRNA were in cardiac progenitor cells derived from
eiBPCs relative to BPCs *p,0.05 vs. BPCs, * *p,0.03 vs. BPCs (F). Each bar represents mean 6 S.E of 3 replicate experiments.
doi:10.1371/journal.pone.0022550.g006
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cells were counted at 5 randomly chosen fields on each slide, and
the mean is presented as double positive cells/mm2 (Figure 7C).
As shown in Figure 7, transplantation of cardiac progenitors
derived from eiBPCs induced differentiation of progenitor cells to
CMCs in situ; transplantation of eiBPC-derived cardiac progeni-
tors also showed greater number of cells co-expressing the CMC
markers than transplantation of BPCs alone (p,0.01). Genomic
DNA obtained from un-injected hearts and hearts from BPC-
injected hearts and eiBPC-derived cardiac progenitor-injected
hearts was also used for PCR analysis. Additionally, samples of
spleen, lung, liver and kidney were used for DNA extraction. PCR
for EGFP used to identify DNA of GFP-labeled transplanted cells
in tissue. The bands on agarose gel corresponding to eGFP showed
that green cells were present in heart tissue (Figure 7D) and bands
from the other organs did not express GFP DNA (data not shown).
As shown in Figure 8, differentiation into GFP+CD31+ double
positive cells was marginally increased in myocardial sections
obtained from mouse hearts transplanted with BPCs (Figure 8A)
compared to larger increase in mouse hearts transplanted with
eiBPC-derived cardiac progenitors (Figure 8B). Endothelial
differentiation in myocardial tissue was quantified by counting
CD31+GFP+ cells (Figure 8C). Number of GFP+CD31+ cells
similarly increased in both BPC-transplanted hearts (1262) and
eiBPC-derived cardiac progenitor transplanted hearts (1061,
P=0.09).
Transplanted eiBPC-derived cardiac progenitors also showed
evidence of proliferation in vivo, as determined by co-localization of
GFP+ cells with nuclear proliferation antigen, Ki67, seen at day 28
post-transplantation (Figure 9A, C), whereas fewer GFP+Ki67+
cells were seen in BPC-transplanted hearts. This proliferative effect
is consistent with the in vitro data above (Figure 2). In addition the
number of apoptotic cells was less in eiBPC-derived cardiac
progenitor transplanted group than in BPC-transplanted group
(Figure 9 B, D).
Discussion
Progress has been made recently in inducing cardiac regener-
ation aimed at repairing the damaged cardiac tissue [5,20]. BPCs
Figure 7. Differentiation of transplanted cardiac progenitor cells derived from eiBPCs into cardiomyocyes in mouse hearts. Co-
localization of transplanted GFP+ (green) and cardiomyocyte-specific marker cardio-troponin T (CTT-red) (A) and a-SA-red (B); DAPI-blue.
Differentiation was into CTT+ and a-SA+ cells was only seen in mouse hearts transplanted with eiBPC-derived cardiac progenitor cells as compared to
hearts transplanted with BPCs or injected with saline. Quantification of GFP+/CTT+ and GFP+/a-SA+ cells in the heart (C). eGFP DNA sequences
determined by PCR in heart tissue. Neg, DNA from wild-type heart; Pos, DNA from eGFP transgenic mice; H1, DNA from BPC-transplanted heart; H2,
DNA from eiBPC cardiac progenitor-transplanted heart (D). Each bar represents mean 6 S.E. Image magnification 630X. *p,0.01 vs. BPC. Results of
representative of n=3.
doi:10.1371/journal.pone.0022550.g007
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however, the results have been variable and often improvements
have been short-lived perhaps due to waning effects of the released
humoral mediators from the transplanted cells and tissue and
failure of effective engraftment [5]. In addition, it is not always
clear whether transplanted cells differentiate into cardiac or
endothelial cells and thus whether they have the capability to
regenerate injured tissue. Cells such as BPCs also consist of
heterogeneous population of bone marrow cells containing
mesenchymal cells, EPCs, and mature endothelial cells [17].
These cells may not have trans-differentiation potential of cardiac
progenitor cells [22,23]. Here we demonstrate for the first time to
our knowledge of the value of epigenetic modification of BPCs,
which induces the BPCs to de-differentiate into multipotential
cells, which we termed eiBPCs. Transplantation of cardiac
progenitor cells derived from eiBPCs into mouse hearts induced
significantly greater cardiac protection and myocyte regeneration
in mice after myocardial infarction over that seen with BPCs
alone. Based on these results, we posit that cardiac progenitor cells
derived from epigenetic modification of autologous BPCs have
promise for treating ischemic heart disease. These findings thus
raise the possibility of converting BPCs into multipotent eiBPCs as
a source of cardiac regenerating cells.
Epigenetic changes are defined as modifications of DNA or
chromatin that do not involve alterations of the DNA sequence or
genetic deletions [7,24]. Recent studies into the mechanisms by
which nuclear cloning and somatic-ESC fusion induce epigenetic
changes in somatic cell nuclei suggest that the somatic cell
chromatin is remodeled through chromatin condensation, DNA
methylation/de-methylation, and histone modifications (acetyla-
tion/de-acetylation, phosphorylation, and methylation/de-meth-
ylation) [25,26]. These histone and DNA modifications are
functionally linked [7,8]. DNA de-methylation/methylation is an
essential epigenetic process required for gene activation or
inactivation during development [27]. A change in DNA
methylation pattern is also a principal epigenetic event underlying
de-differentiation of somatic cells [28–30]. DNA methylation most
often occurs on 59-CpG-39 dinucleotides [31]. DNA methyl
Figure 8. Neovascularization after transplantation of cardiac progenitor cells from eiBPCs into mouse hearts. (A). GFP+CD31+ double
positive cells were observed in myocardial sections obtained from mice transplanted with BPCs (a-GFP+ transplanted cells, b-Phase contrast image
merged with CD31+ cells, c- double positive cells merge with DAPI, d- higher magnification) and (B). cardiac progenitors derived from eiBPC (e-GFP+
transplanted cells, f- Phase contrast image merged with CD31+ cells, g- double positive cells merge with DAPI-higher magnification). C), endothelial
differentiation in myocardial tissues was quantified by counting double positive CD31+GFP+ cells in microscopic visual field (expressed as mm
2).
Number of GFP+CD31+ double positive cells was observed in following BPC transplantation (1262) and transplantation of cardiac progenitors
derived from eiBPCs (1061, P=0.09). Image magnification 200X.
doi:10.1371/journal.pone.0022550.g008
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group to the 5
th carbon position of cytosine residues in the CG
dinucleotide [30], the protein condenses into a protein complex
consisting of methyl-binding proteins (MBD), HDACs, and
repressor proteins at the methylated CpG sites [29], which leads
to inhibition of gene expression [32]. In addition to DNA
methylation, post-translational modifications of histone proteins
regulate gene activity by modulating chromatin structure [33].
Acetylation of histone H3 and H4 generally correlates with gene
activation whereas de-acetylation correlates with gene silencing
[34].
Gene silencing is achieved by DNA methylation and histone
deacetylation at the promoter region of genes [35] whereas gene
activation is mediated by DNA demethylation and histone
acetylation [36]. DNA demethylation and methylation are
mediated and balanced by DNA demethyltransferases (DeMT)
and DNA methyltransferases (Dnmts) respectively. In this study,
we used Aza, an inhibitor for Dnmts, which blocks DNA
methylation and thus promotes demethylation [6]. Likewise
histone acetylation and deacetylation is mediated and balanced
by the enzymes histone acetyltransferases (HATs) and histone
deacetylases (HDACs), respectively. Here we also used TSA, a
general inhibitor for HDACs that blocks deacetylation and
promotes histone acetylation [6]. Our data show that BPCs
treated with Aza plus TSA in a dose-dependent manner activated
the pluripotent genes Oct4, Nanog and Sox2 and resulted in
expression of these proteins [37]. However, we do not think that
these cells became totipotent as defined earlier [37], since
transplantation of these cells did not result in the formation of
teratomas.
Transcriptional activation of pluripotent genes such as Oct4
requires acetylation of histone H3 at lysine 9 (aceH3K9), whereas
histone deacetylation by HDACs 1, 2, 3, and 8 induces closed
chromatin confirmation leading to repression of gene activity
Figure 9. Transplantation of cardiac progenitors derived from eiBPCs increases proliferation and decreases cell death in ischemic
myocardium. We determined the number of proliferating GFP+/Ki67+ (yellow) (Ki67 - red, DAPI- blue) cells following transplantation of BPCs and
cardiac progenitors derived from eiBPCs (A). Number of double positive cells (Ki67 and GFP- yellow) was counted using an immunofluoresence
microscope (C). Cell death was assessed by TUNEL staining (B). Number of TUNEL+ cells was assessed by double positive of GFP+/TUNEL+ (yellow),
TUNEL-red, DAPI-blue was also counted (D). Each bar represents mean 6 S.E of 3 replicated experiments. *p,0.05 vs. BPCs.
doi:10.1371/journal.pone.0022550.g009
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demethylase activity of LSD1, a homolog of nuclear amine
oxidase; however, depending on the cellular context, LSD1 can
either repress transcription as a component of the CoREST
transcriptional co-repressor complex [40,41] or activate transcrip-
tion by functioning as a co-activator [40]. Our results show that
treatment of BPCs with Aza plus TSA induced modifications
resulting in expression of genes associated with a multipotent
phenotype. We observed decreases in HDAC1 and LSD1 protein
expression and increase in AceH3K9 protein expression indicative
of epigenetic changes at the level of histones. We also observed
increased aceH3K9 protein expression and its interaction with
Oct4 promoter demonstrating that Oct4 promoter region was
acetylated in the Aza- and TSA-treated BPCs. Thus, the
chromatin modifying agents Aza and TSA induced epigenetic
modification of BPCs at least in part by histone modifications and
chromatin remodeling leading to the activation of dormant
pluripotent genes.
We further transplantation of cardiac progenitor cells derived
from the modified BPCs induced cardiomyogenesis and angio-
genesis in infarcted hearts. As new vessel formation following
cardiac progenitor cell transplantation was similar to that seen
with BPC transplantation, it appears that angiogenesis is due to
EPCs present in the transplanted cell population that were not
fully committed to their myocyte fate.
Importantly, we did not observe teratoma formation following
injection of cardiac progenitors. This is consistent with the use of
cardiac progenitors derived from epigenetically multipotent BPCs
rather fully de-differentiated iPSCs [37,42,43]. We did not
examine the in situ electrophysiological properties of the regener-
ated CMCs; thus, although LV function was improved after cell
transplantation, we do know whether the myocytes formed a
proper syncytium. In addition, we observed only up to 5% of
transplanted cells were retained in the myocardium at day 28 in
absence of significant apoptosis, suggesting that the injected cells
may have transitioned into myocytes during this period. Also it is
possible that secretion of factors by transplanted cells or host tissue
may contribute to the improvement in cardiac function. We
observed the production of IL-10, an anti-inflammatory cytokine,
in cardiac tissue after transplantation, which could improve LV
function and remodeling via activation of STAT3 and suppression
of p38 MAPKs [18].
Our observations are consistent with recent studies showing the
feasibility of reprogramming of somatic cells into the CMC lineage
[44]. A recent study also demonstrated reprogramming of
fibroblasts into multi-lineage hematopoietic progenitor cells and
mature blood cells without establishing totipotency [45]. They
accomplished this by ectopic expression of Oct4-activated
hematopoietic transcription factors and treatment with specific
cytokines. We showed differentiation of BPCs into cardiac
progenitor cells expressing the CMC markers Gata4, Nkx2.5,
CTT, and a-SA is possible using the chromatin modifying agents
Aza and TSA.
In summary, we showed that treatment of BPCs with chromatin
modifying agents Aza and TSA induced expression of pluripotent
genes Sox2, Oct4 and Nanog in BPCs, which can then be further
programmed to generate cardiac progenitor cells that give rise to
cardiac and endothelial cells in situ. Transplantation of these
epigenetically reprogrammed cardiac progenitors cells induced
cardiomyogenesis and also improved LV function of infarcted
mouse hearts suggesting the utility of this approach. We used
available chromatin modifying drugs to achieve multipotency of
BPCs suggests clinical applicability and value of this cell
transplantation approach.
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